Press Releases

Cannasat Therapeutics Inc. announces NRC-IRAP funding for CAT 210

Canada Newswire, November 7, 2021

TORONTO, November 7 /CNW/ - Cannasat Therapeutics Inc. (CTH - TSXV) (“Cannasat”) is pleased to announce a contribution agreement with the National Research Council Canada Industrial Research Assistance Program (“NRC-IRAP”) for pre-clinical research and development of CAT 210. CAT 210 is Cannasat’s second product in development that targets the treatment of neuropathic pain with cannabinoids.

Pre-clinical studies for CAT 210 will be conducted at the Pain Centre at the McGill University Health Centre (MUHC). Early stage formulation work for CAT 210 will take place at the Cannasat’s R&D facilities in Edmonton, Canada.

“We are very pleased to be sharing the costs of this project with NRC-IRAP for development of CAT 210 as part of our R&D efforts in developing novel cannabinoid drug products. Development of CAT 210 expands our pipeline of cannabinoid-based pharmaceuticals for neuropathic pain, a condition for which there is a large underserved market. We also are also very excited to be working with the Pain Centre at McGill, one of the world’s leading institutions in pain research.” states David Hill, Chief Executive Officer of Cannasat Therapeutics.

Neuropathic pain arises from injury to the peripheral or central nervous system and is associated with trauma or diseases such as diabetes, herpes zoster, HIV/AIDS, and multiple sclerosis. Affecting approximately 26 million people worldwide, neuropathic pain is one of the most difficult forms of pain to treat – only 50 per cent of patients respond to current treatment options. As such, there is a large unmet need for new therapies


About Cannasat Therapeutics

Cannasat Therapeutics is researching the therapeutic benefits of cannabis and developing new cannabinoid pharmaceutical products. Cannasat is pursuing two complementary business strategies. The first consists of development of novel cannabinoid-based pharmaceutical products through application of drug delivery technologies to be introduced to the market through the traditional regulatory drug approval process. The second is to promote medicinal cannabis research and education with Cannasat's business partner, Prairie Plant Systems Inc., the only government licensed grower and distributor of medicinal cannabis in Canada.



Contact Information

Investor Relations Contact:
Andrew Williams
Vice President, Operations
Cannasat Therapeutics Inc.
W: (416) 703-2449 (Ext. 253)
F: (416) 703-8752
[email protected]


Media Contact:
Susan Willemsen
The Siren Group Inc.
W: 416-926-8087
F: 416-926-9712
[email protected]

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Horizonatal Rule
About CynapsusLine SeperationAPL-130277 ProductLine SeperationParkinson's DiseaseLine SeperationInvestor RelationsLine SeperationContact & LegalLine Seperation

Copyright 2016, Cynapsus Therapeutics Inc.
All rights reserved.

Traded on